WO2001058484A3 - Novel uses of mammalian ccr8 receptors and related reagents - Google Patents

Novel uses of mammalian ccr8 receptors and related reagents Download PDF

Info

Publication number
WO2001058484A3
WO2001058484A3 PCT/US2001/004161 US0104161W WO0158484A3 WO 2001058484 A3 WO2001058484 A3 WO 2001058484A3 US 0104161 W US0104161 W US 0104161W WO 0158484 A3 WO0158484 A3 WO 0158484A3
Authority
WO
WIPO (PCT)
Prior art keywords
related reagents
methods
mammalian
novel uses
reagents
Prior art date
Application number
PCT/US2001/004161
Other languages
French (fr)
Other versions
WO2001058484A2 (en
Inventor
Sergio A Lira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU2001236802A priority Critical patent/AU2001236802A1/en
Publication of WO2001058484A2 publication Critical patent/WO2001058484A2/en
Publication of WO2001058484A3 publication Critical patent/WO2001058484A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Compositions and methods for using mammalian CCR8 receptor proteins, antagonists and related reagents to treat diseases or conditions associated with Th2-mediated responses in an individual, especially asthma, are provided. The methods comprise administering a therapeutically effective amount of a CCR8 antagonist, alone or in combination with other therapeutic reagents. Also provided are methods for screening for therapeutics. Genetically-engineered animals and their use as models of molecular mechanism are also provided.
PCT/US2001/004161 2000-02-10 2001-02-09 Novel uses of mammalian ccr8 receptors and related reagents WO2001058484A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236802A AU2001236802A1 (en) 2000-02-10 2001-02-09 Novel uses of mammalian ccr8 receptors and related reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18163800P 2000-02-10 2000-02-10
US60/181,638 2000-02-10

Publications (2)

Publication Number Publication Date
WO2001058484A2 WO2001058484A2 (en) 2001-08-16
WO2001058484A3 true WO2001058484A3 (en) 2002-02-21

Family

ID=22665136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004161 WO2001058484A2 (en) 2000-02-10 2001-02-09 Novel uses of mammalian ccr8 receptors and related reagents

Country Status (2)

Country Link
AU (1) AU2001236802A1 (en)
WO (1) WO2001058484A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229753A1 (en) * 2002-05-13 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
US7491827B2 (en) 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN117098561A (en) * 2020-08-28 2023-11-21 和铂医药美国股份有限公司 CCR8 antibodies and uses thereof
WO2023206350A1 (en) * 2022-04-29 2023-11-02 Analytical Biosciences Shanghai Limited Anti-ccr8 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006561A2 (en) * 1997-07-29 1999-02-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Chemokine receptor ccr8 dna and uses thereof
WO1999025734A2 (en) * 1997-11-13 1999-05-27 Schering Corporation Th2 CELL DEPLETION; COMPOSITIONS; METHODS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006561A2 (en) * 1997-07-29 1999-02-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Chemokine receptor ccr8 dna and uses thereof
WO1999025734A2 (en) * 1997-11-13 1999-05-27 Schering Corporation Th2 CELL DEPLETION; COMPOSITIONS; METHODS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUTTICHAU HANS R ET AL: "A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 1, 3 January 2000 (2000-01-03), pages 171 - 179, XP001008530, ISSN: 0022-1007 *
NAPOLITANO M. ET AL.: "Structure and function of the CC chemokine receptor (CCR) 8", FORUM (GENOVA), vol. 9, no. 4, 1999, pages 315 - 324, XP001012929 *

Also Published As

Publication number Publication date
WO2001058484A2 (en) 2001-08-16
AU2001236802A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
WO2004022718A3 (en) Therapeutic human anti-il-1r1 monoclonal antibody
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
NZ592973A (en) Compositions and methods of using angiopoietin-like 4 protein
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
EE05212B1 (en) Use of a Pol Peptide for the Preparation of a Pharmaceutical Composition for the Treatment of a Tumor Cell Expressing APRIL
WO2006020580A3 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
FI960727A (en) Heterocycles useful as neurokinin antagonists
DE602005001445D1 (en) N-TERMINAL MONOPEGYLATED HUMAN GROWTH HORMONE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
NZ522326A (en) Adenosine A2A receptor antagonists
WO2002036625A3 (en) Prokineticin polypeptides, related compositions and methods
HK1105197A1 (en) Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
WO2003004045A3 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
CA2530027A1 (en) Novel melanocortin receptor templates, peptides, and use thereof
WO2001058484A3 (en) Novel uses of mammalian ccr8 receptors and related reagents
WO2001064877A3 (en) Human schizophrenia gene
AU9363398A (en) Hepatitis c receptor protein cd81
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
WO2001064876A3 (en) Human schizophrenia gene
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
PT1655032E (en) Use of the p2x7 antagonists o-atp or bbg for the treatment of the neurodegenerative phase of multiple sclerosis
TW429262B (en) C5a receptor antagonists having substantially no agonist activity
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
AU2003250128A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP